{
    "nct_id": "NCT05007418",
    "official_title": "A Phase 1b, Open-Label Study of the Safety and Efficacy of Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor (DAR)-T Cells in Patients With Relapsed or Refractory Multiple Myeloma",
    "inclusion_criteria": "* Must have relapsed or refractory multiple myeloma (RRMM) after having received prior lines of anti-myeloma treatments.\n* Measurable disease as defined by one of the following: abnormal serum or M-protein levels; abnormal serum free light chain (FLC) assay; ≥ 30% clonal plasma cells in the bone marrow aspirate or biopsy sample\n* Evidence of cell membrane CD38 expression as determined by immunohistochemistry (IHC) analysis ofbone marrow biopsy or extramedullary plasmacytoma\n* Pulse oximetry ≥ 92% on room air\n* Have a life expectancy ≥ 12 weeks\n* Be willing and able to comply with the study schedule and all study requirements\n* Willing to follow contraception guidelines\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Previous treatment with any systemic therapy for multiple myeloma within 14 days prior to start of study dose\n* Treatment with any cellular therapy within 8 weeks prior to start of study dose\n* Have any unresolved toxicity ≥ Grade 2 from previous anticancer therapies\n* A history of brain metastasis or spinal cord compression\n* Has an ECOG performance status (PS) ≥ 3\n* Has received allogeneic hematopoietic stem cell transplantation (HSCT) within 6 months, has active graft-versus-host disease (GvHD) following transplant, or is currently receiving immunosuppressive therapy following transplant\n* Has any clinically significant low baseline lab results for hemoglobin, platelet counts, and neutrophil counts at screening unless resulting from underlying RRMM\n* Has any clinically significant elevated baseline lab results for serum creatinine, AST or β2 microglobulin\n* Abnormal INR or aPTT, unless on a stable dose of an anticoagulant\n* Has known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C\n* Is currently pregnant or breast feeding or planning on either during the study.\n* Has an active bacterial, viral, or fungal infection\n* Has active plasma cell leukemia\n* Has extramedullary plasmacytoma(s)\n* Has any significant medical condition, abnormality, or psychiatric illness that would prevent study participation\n* Has left ventricular ejection fraction (LVEF) < 40%\n* Has second primary malignancies (SPMs) in addition to multiple myeloma if the SPM has required therapy within the last 3 years or is not in complete remission\n* Has any additional clinical history of the CNS or cardiovascular disease that would place the patient at an unacceptable risk if the patient participates in the study",
    "miscellaneous_criteria": ""
}